These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34424568)

  • 21. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
    Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
    Sato H; Jeggo PA; Shibata A
    Cancer Sci; 2019 Nov; 110(11):3415-3423. PubMed ID: 31513320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
    Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren HG; Nahi H; Wagner AK; Alici E
    Cancer Immunol Immunother; 2023 May; 72(5):1153-1167. PubMed ID: 36355079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis.
    Zhou J; Peng H; Li K; Qu K; Wang B; Wu Y; Ye L; Dong Z; Wei H; Sun R; Tian Z
    Immunity; 2019 Feb; 50(2):403-417.e4. PubMed ID: 30709740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.
    Kravtsova-Ivantsiv Y; Goldhirsh G; Ivantsiv A; Ben Itzhak O; Kwon YT; Pikarsky E; Ciechanover A
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29823-29831. PubMed ID: 33168738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
    Dhupkar P; Gordon N; Stewart J; Kleinerman ES
    Cancer Med; 2018 Jun; 7(6):2654-2664. PubMed ID: 29733528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.